JP2002541255A5 - - Google Patents

Download PDF

Info

Publication number
JP2002541255A5
JP2002541255A5 JP2000610851A JP2000610851A JP2002541255A5 JP 2002541255 A5 JP2002541255 A5 JP 2002541255A5 JP 2000610851 A JP2000610851 A JP 2000610851A JP 2000610851 A JP2000610851 A JP 2000610851A JP 2002541255 A5 JP2002541255 A5 JP 2002541255A5
Authority
JP
Japan
Prior art keywords
inhibition
binds
tyrosine kinases
family tyrosine
kinases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000610851A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002541255A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2000/009512 external-priority patent/WO2000061578A1/en
Publication of JP2002541255A publication Critical patent/JP2002541255A/ja
Publication of JP2002541255A5 publication Critical patent/JP2002541255A5/ja
Pending legal-status Critical Current

Links

Images

JP2000610851A 1999-04-09 2000-04-07 Her族チロシンキナーゼの分解および/または阻害方法および組成物 Pending JP2002541255A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12859399P 1999-04-09 1999-04-09
US60/128,593 1999-04-09
PCT/US2000/009512 WO2000061578A1 (en) 1999-04-09 2000-04-07 Methods and compositions for degradation and/or inhibition of her-family tyrosine kinases

Publications (2)

Publication Number Publication Date
JP2002541255A JP2002541255A (ja) 2002-12-03
JP2002541255A5 true JP2002541255A5 (cg-RX-API-DMAC7.html) 2007-07-05

Family

ID=22436066

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000610851A Pending JP2002541255A (ja) 1999-04-09 2000-04-07 Her族チロシンキナーゼの分解および/または阻害方法および組成物

Country Status (6)

Country Link
US (1) US7271160B2 (cg-RX-API-DMAC7.html)
EP (1) EP1169319A4 (cg-RX-API-DMAC7.html)
JP (1) JP2002541255A (cg-RX-API-DMAC7.html)
AU (1) AU769235B2 (cg-RX-API-DMAC7.html)
CA (1) CA2370007A1 (cg-RX-API-DMAC7.html)
WO (1) WO2000061578A1 (cg-RX-API-DMAC7.html)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6372712B1 (en) 1998-05-22 2002-04-16 The Board Of Trustees Of The Leland Stanford Jr. University Synthetic bifunctional molecules containing a drug moiety and presenter protein ligand
US6887842B1 (en) * 1999-11-19 2005-05-03 The Board Of Trustees Of The Leland Stanford Junior University Modulating a pharmacokinetic property of a drug by administering a bifunctional molecule containing the drug
US7220552B1 (en) 1999-11-19 2007-05-22 The Board Of Trustees Of The Leland Stanford Junior University Bifunctional molecules and their use in the disruption of protein-protein interactions
AU2044001A (en) 1999-11-19 2001-05-30 Board Of Trustees Of The Leland Stanford Junior University Targeted bifunctional molecules and therapies based thereon
US20020002169A1 (en) 1999-12-08 2002-01-03 Griffin John H. Protein kinase inhibitors
US6946456B2 (en) 2000-07-28 2005-09-20 Sloan-Kettering Institute For Cancer Research Methods for treating cell proliferative disorders and viral infections
ATE328888T1 (de) 2000-08-25 2006-06-15 Sloan Kettering Inst Cancer Radicicol und monocillin und ihre analogen und ihre anwendungen
US7439359B2 (en) 2000-11-02 2008-10-21 Sloan-Kettering Institute For Cancer Research Small molecule compositions for binding to hsp90
US7825094B2 (en) 2001-05-23 2010-11-02 Sloan-Kettering Institute For Cancer Research Method of treatment for cancers associated with elevated HER 2 levels
US6872715B2 (en) * 2001-08-06 2005-03-29 Kosan Biosciences, Inc. Benzoquinone ansamycins
EP1923061A1 (en) 2001-09-24 2008-05-21 Conforma Therapeutic Corporation Process for preparing 17-Allyl amino geldanamycin (17-AAG) and other ansamycins
JP2005504086A (ja) 2001-09-24 2005-02-10 コンフォーマ セラピューティクス コーポレーション 17−アリルアミノゲルダナマイシン(17−aag)および他のアンサマイシン類を製造する方法
GB0202871D0 (en) * 2002-02-07 2002-03-27 Cancer Res Ventures Ltd Assays,methods and means
US7259156B2 (en) 2004-05-20 2007-08-21 Kosan Biosciences Incorporated Geldanamycin compounds and method of use
KR20070050918A (ko) * 2004-07-02 2007-05-16 뉴텍 파마 피엘씨 암의 치료
US20060105941A1 (en) * 2004-11-12 2006-05-18 Allergan, Inc. Mixed antibiotic codrugs
BRPI0609509A2 (pt) 2005-03-30 2010-04-13 Conforma Therapeutics Corp composto ou um polimorfo, solvato, tautÈmero, enanciÈmero, pró-droga ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso do composto, polimorfo, solvato, tautÈmero, enanciÈmero, pró-droga ou sal farmaceuticamente aceitável
ES2645095T3 (es) 2006-06-30 2017-12-04 Sloan-Kettering Institute For Cancer Research Tratamiento de enfermedades neurodegenerativas a través de la inhibición de Hsp90
US20100113355A1 (en) 2007-04-27 2010-05-06 Naresh Chennamsetty Novel antibody molecules and nucleic acids binding to fungal stress protein hsp90
WO2010028389A1 (en) * 2008-09-08 2010-03-11 The Methodist Hospital Research Institute Image-guided energy deposition for targeted drug delivery
PT2486039T (pt) 2009-10-07 2016-09-06 Sloan Kettering Inst For Cancer Res Derivados de purina úteis como inibidores de hsp90
AU2012240077C1 (en) 2011-04-05 2017-08-10 Sloan-Kettering Institute For Cancer Research Hsp90 inhibitors
MX354215B (es) 2011-04-05 2018-02-19 Sloan Kettering Inst Cancer Res Inhibidores de la proteina 90 de choque termico (hsp90).
WO2012167261A2 (en) 2011-06-03 2012-12-06 Yale University Compositions and methods for treating and preventing neointimal stenosis
US20140079636A1 (en) 2012-04-16 2014-03-20 Dinesh U. Chimmanamada Targeted therapeutics
EP3738594A1 (en) 2013-09-10 2020-11-18 Madrigal Pharmaceuticals, Inc. Targeted therapeutics having an hsp90 ligand as binding moiety
WO2015066053A2 (en) 2013-10-28 2015-05-07 Synta Pharmaceuticals Corp. Targeted therapeutics
EP3099332A4 (en) 2014-01-29 2017-06-21 Madrigal Pharmaceuticals, Inc. Targeted therapeutics
JP6576942B6 (ja) 2014-03-03 2019-11-27 マドリガル ファーマシューティカルズ インコーポレイテッド 標的治療薬
MA39483A (fr) 2014-03-18 2015-09-24 Synta Pharmaceuticals Corp Agents thérapeutiques cibles
US11377447B2 (en) 2017-06-20 2022-07-05 Madrigal Pharmaceuticals, Inc. Targeted therapeutics
US11491145B2 (en) 2017-06-20 2022-11-08 Madrigal Pharmaceuticals, Inc. Combination therapies comprising targeted therapeutics
CN117700313B (zh) * 2023-12-14 2025-02-14 怒江绿色香料产业研究院 一种羟基十四烯醛及其制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4261989A (en) * 1979-02-19 1981-04-14 Kaken Chemical Co. Ltd. Geldanamycin derivatives and antitumor drug
JPS55111469A (en) * 1979-02-19 1980-08-28 Kaken Pharmaceut Co Ltd Novel geldanamycin derivative, its preparation, and antitumor drug comprising it as active ingredient
US5650430A (en) 1990-06-06 1997-07-22 Sankyo Company, Limited Radicicol derivatives, their preparation and their anti-tumor activity
CA2052907A1 (en) * 1990-10-11 1992-04-12 Joseph P. Vacca Hiv protease inhibitors having symmetrical structure
EP0706516A1 (en) * 1993-06-29 1996-04-17 Pfizer Inc. Ansamycin derivatives as antioncogene and anticancer agents
US5932566A (en) * 1994-06-16 1999-08-03 Pfizer Inc. Ansamycin derivatives as antioncogene and anticancer agents
NZ331062A (en) 1996-10-25 2000-05-26 Kyowa Hakko Kogyo Company Ltd Radicicol derivatives or pharmacologically acceptable salts which show tyrosine kinase inhibition activity and have antitumor effects
ATE460423T1 (de) * 1997-05-14 2010-03-15 Sloan Kettering Inst Cancer Verfahren und zubereitungen zur zerstörung bestimmter proteine
US5968921A (en) * 1997-10-24 1999-10-19 Orgegon Health Sciences University Compositions and methods for promoting nerve regeneration

Similar Documents

Publication Publication Date Title
IS2376B (is) Þíenópýrimidíndíón og notkun þeirra í breytingu ásjálfsnæmissjúkdómi
IS6658A (is) Ný efnasambönd
JP2004534850A5 (cg-RX-API-DMAC7.html)
PT1263724E (pt) Novos compostos
ATE361287T1 (de) Neue indol-2-on derivate
SE0104251D0 (sv) Novel compounds
RU2002109240A (ru) Применение ретигабина для невропатических болей
EA200100412A1 (ru) Замещенные 3-цианохинолины в качестве ингибиторов протеинтирозинкиназ
HRP20031003A2 (en) 4'-substituted nukleosides
JP2004514660A (ja) Hsp90に結合するための小分子組成物
BG66080B1 (bg) Заместени тиоацетамиди
RU94042922A (ru) Новые соединения, способы их получения, фармацевтическая композиция
ATE316083T1 (de) Adamantanderivate
JP2003531157A5 (cg-RX-API-DMAC7.html)
EA200301159A1 (ru) Цитотоксические иммуноконъюгаты антитела к cd44
CA2343236A1 (en) 4,4-biarylpiperidine derivatives
ATE230392T1 (de) Amidinophenyl-pyrrolidine, -pyrroline und - isoxazolidine und ihre derivate
NO974694L (no) Farmasöytisk preparat som inneholder N-fosfonoglycin-derivater for å inhibere vekst av cancer og virus
IL153680A0 (en) Aplidine derivatives and methods for the preparation thereof
CY1110258T1 (el) Υποκατεστημενα παραγωγα c-κυκλοεξυλομεθυλαμινης
ATE238981T1 (de) Antitumorwirkstoffe
WO2003017939A3 (en) Piperazinone compounds as anti-tumor and anti-cancer agents and methods of treatment
SE0003476D0 (sv) Compounds
WO2001066551A8 (en) Azole compounds as therapeutic agents for fungal infections
WO2000074700A3 (en) Uses of ouabain and ouabain-like molecules in apoptosis related pathologies